A new study shows the impact on recurrence by using PDD in bladder tumor management

Published: 10 March 2021Medical Information
**A recently published systematic review and network meta-analysis of randomized controlled trials investigated the impact of enhanced optical techniques at time of TURBT* with or without single immediate intravesical chemotherapy (SIIC) on recurrence rate of non-muscle-invasive bladder cancer (NMIBC).** The study is a meta-analysis of optical enhancement techniques with or without single immediate intravesical chemotherapy, assessing the effect on 12-month recurrence. Its objective was to determine optimal initial bladder tumor management based on a combination of different optical techniques during TURBT and SIIC. Photodynamic diagnosis (PDD) techniques using blue light, and Narrow-band imaging (NBI) were assessed separately, against a control arm of white light cystoscopy alone. The global analysis included randomized control trials only, and only studies that involved all risk categories of patients. The primary outcome of interest was the recurrence rate during the first year after TURBT. The meta-analysis findings support the combination of PDD at the time of TURBT and concomitant SIIC as the optimal initial treatment in patients with non-muscle invasive bladder cancer. The Use of PDD was able to reduce the 12-month recurrence rate; moreover, a concomitant SIIC increased this risk benefit by 32% additional reduction of odds ratio. NBI with or without SIIC were not associated with a significantly lower likelihood of 12‐month recurrence rate. Read the full study abstract here: https://pubmed.ncbi.nlm.nih.gov/33683778/ *TURBT: trans-urethral resection of bladder tumors

News and events